High materiality8/10
Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim
Why it may matterVerify against the original reporting
Long-term upside remains despite a marginal target downgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim lowers AVTX target to $48 from $50; current price around $18.70. Despite the downgrade, the stock still offers meaningful long-term upside versus the current level.
- Guggenheim lowers AVTX target to $48; current price ~ $18.70; upside remains significant.
Key facts
- 01
Target: $48
- 02
Posted price: $18.7
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.